EA201491387A1 - Способ получения вакцины, содержащей по меньшей мере два антигена, способных адсорбироваться на оксигидроксиде алюминия - Google Patents

Способ получения вакцины, содержащей по меньшей мере два антигена, способных адсорбироваться на оксигидроксиде алюминия

Info

Publication number
EA201491387A1
EA201491387A1 EA201491387A EA201491387A EA201491387A1 EA 201491387 A1 EA201491387 A1 EA 201491387A1 EA 201491387 A EA201491387 A EA 201491387A EA 201491387 A EA201491387 A EA 201491387A EA 201491387 A1 EA201491387 A1 EA 201491387A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
adsorbed
alooh
adaptable
obtaining
Prior art date
Application number
EA201491387A
Other languages
English (en)
Other versions
EA026058B1 (ru
Inventor
Ландри Берто
Изабелль Шакорнак
Ален Франсон
Жан-Франсуа О
Сандрин Лентш Граф
Original Assignee
Санофи Пастер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи Пастер filed Critical Санофи Пастер
Publication of EA201491387A1 publication Critical patent/EA201491387A1/ru
Publication of EA026058B1 publication Critical patent/EA026058B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Объектом изобретения является способ получения вакцинной композиции, содержащей по меньшей мере оксигидроксид алюминия (AlOOH) и, по меньшей мере, поверхностный антиген гепатита В, и антиген Haemophilus influenzae типа b. В соответствии с изобретением поверхностный антиген гепатита В сохраняется адсорбированным на AlOOH, тогда как антиген Hib сохраняется неадсорбированным. С этой целью поверхностный антиген гепатита В адсорбируют на AlOOH для получения комплекса AlOOH/HBsAg, затем указанный комплекс AlOOH/HBsAg смешивают с антигеном Hib в присутствии катионных аминокислот в концентрации по меньшей мере 100 мг/л и фосфатных ионов в концентрации от 35 до 45 ммоль/л.
EA201491387A 2012-01-17 2013-01-17 Способ получения вакцинной композиции, содержащей поверхностный антиген вируса гепатита b и антиген haemophilus influenzae типа b EA026058B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1250464A FR2985663B1 (fr) 2012-01-17 2012-01-17 Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
PCT/FR2013/050106 WO2013107988A1 (fr) 2012-01-17 2013-01-17 Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium

Publications (2)

Publication Number Publication Date
EA201491387A1 true EA201491387A1 (ru) 2014-12-30
EA026058B1 EA026058B1 (ru) 2017-02-28

Family

ID=47714410

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491387A EA026058B1 (ru) 2012-01-17 2013-01-17 Способ получения вакцинной композиции, содержащей поверхностный антиген вируса гепатита b и антиген haemophilus influenzae типа b

Country Status (34)

Country Link
US (1) US9358294B2 (ru)
EP (1) EP2804628B1 (ru)
JP (2) JP6199310B2 (ru)
KR (1) KR102019848B1 (ru)
CN (1) CN104039348B (ru)
AP (1) AP2014007848A0 (ru)
AR (1) AR089737A1 (ru)
AU (1) AU2013210927B2 (ru)
BR (1) BR112014017416B1 (ru)
CA (1) CA2861304C (ru)
CR (1) CR20140356A (ru)
CY (1) CY1119206T1 (ru)
DK (1) DK2804628T3 (ru)
EA (1) EA026058B1 (ru)
ES (1) ES2625011T3 (ru)
FR (1) FR2985663B1 (ru)
GE (1) GEP201706642B (ru)
GT (1) GT201400120A (ru)
HK (1) HK1204293A1 (ru)
HR (1) HRP20170692T1 (ru)
HU (1) HUE032539T2 (ru)
IL (1) IL233643A (ru)
LT (1) LT2804628T (ru)
MX (1) MX349411B (ru)
NZ (1) NZ627345A (ru)
PE (1) PE20141515A1 (ru)
PH (1) PH12014501546A1 (ru)
PL (1) PL2804628T3 (ru)
PT (1) PT2804628T (ru)
RS (1) RS55962B1 (ru)
SI (1) SI2804628T1 (ru)
UA (1) UA113000C2 (ru)
WO (1) WO2013107988A1 (ru)
ZA (1) ZA201405431B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
KR20230173114A (ko) 2021-04-20 2023-12-26 케이엠 바이올로직스 가부시키가이샤 6종 혼합 액상 백신 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283910B6 (cs) * 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1414433B1 (en) 2001-08-07 2006-04-12 Laboratoires SMB SA Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Also Published As

Publication number Publication date
SI2804628T1 (sl) 2017-06-30
CN104039348A (zh) 2014-09-10
ZA201405431B (en) 2015-12-23
US20140370049A1 (en) 2014-12-18
AU2013210927A1 (en) 2014-08-28
EP2804628A1 (fr) 2014-11-26
FR2985663B1 (fr) 2015-03-27
CR20140356A (es) 2014-08-28
UA113000C2 (uk) 2016-11-25
CA2861304A1 (fr) 2013-07-25
DK2804628T3 (en) 2017-05-22
AR089737A1 (es) 2014-09-10
PL2804628T3 (pl) 2017-08-31
JP6356886B2 (ja) 2018-07-11
AP2014007848A0 (en) 2014-08-31
MX349411B (es) 2017-07-27
ES2625011T3 (es) 2017-07-18
BR112014017416A8 (pt) 2017-07-04
KR20140119109A (ko) 2014-10-08
PH12014501546B1 (en) 2014-10-08
CY1119206T1 (el) 2018-02-14
HRP20170692T1 (hr) 2017-07-14
CN104039348B (zh) 2016-05-11
GEP201706642B (en) 2017-03-27
JP2017203043A (ja) 2017-11-16
IL233643A0 (en) 2014-08-31
US9358294B2 (en) 2016-06-07
AU2013210927B2 (en) 2017-02-23
PE20141515A1 (es) 2014-11-04
WO2013107988A1 (fr) 2013-07-25
NZ627345A (en) 2016-07-29
FR2985663A1 (fr) 2013-07-19
HUE032539T2 (hu) 2017-10-30
CA2861304C (fr) 2021-05-25
GT201400120A (es) 2015-09-17
JP6199310B2 (ja) 2017-09-20
IL233643A (en) 2017-04-30
KR102019848B1 (ko) 2019-09-09
MX2014007850A (es) 2014-08-21
LT2804628T (lt) 2017-05-25
EP2804628B1 (fr) 2017-03-01
PH12014501546A1 (en) 2014-10-08
PT2804628T (pt) 2017-04-21
HK1204293A1 (en) 2015-11-13
EA026058B1 (ru) 2017-02-28
BR112014017416B1 (pt) 2022-08-16
BR112014017416A2 (pt) 2021-05-25
RS55962B1 (sr) 2017-09-29
JP2015504085A (ja) 2015-02-05

Similar Documents

Publication Publication Date Title
EA201891366A1 (ru) Гуманизированные антитела против cd73
WO2013048883A3 (en) Anti-erbb3 antibodies and uses thereof
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
TN2015000247A1 (en) Bcma antigen binding proteins
MX2022014885A (es) Anticuerpos anti-c5 y metodos de uso.
EA201390341A1 (ru) Адсорбция иммунопотенциаторов на нерастворимых солях металлов
WO2012165815A3 (ko) 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
TN2013000342A1 (en) Sildenafil-free base-containing film preparation and method for producing same
EA201491387A1 (ru) Способ получения вакцины, содержащей по меньшей мере два антигена, способных адсорбироваться на оксигидроксиде алюминия
GB201105981D0 (en) Novel process
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2015051079A3 (en) Phosphohistidine mimetics and antibodies to same
WO2010132047A8 (en) Guanosine/gmp gels and uses thereof
EP3466441A3 (en) Immunological methods of inhibiting gonad maturation
RU2012134847A (ru) Способ определения стадии дефицита железа
WO2012108675A3 (ko) 금속 분리 가능한 pna 앱타머
TH149877A (th) วิธีสำหรับการผสมสูตรวัคซีนที่มีแอนติเจนอย่างน้อยสองชนิดที่สามารถดูดซับบนอลูมิเนียม ออกซิไฮดรอกไซด์
MY191596A (en) Igf-1r antibody and its use for the diagnosis of cancer
RU2013101313A (ru) СПОСОБ ДИФФУЗИИ БОРА ДЛЯ ФОРМИРОВАНИЯ р-ОБЛАСТИ
IN2015DN02993A (ru)
Gil et al. Depth Map Processing for Improving Stereoscopic Image and CGH
KR20160002330U (ko) 끼우는라이트
MY181090A (en) Subterranean treatment with compositions including hexaaquaaluminum trihalide
UA106144C2 (ru) Гибридный селективный к мышьяку сорбент, способ его получения, способ очистки воды от примесей мишьяка и наполнитель картриджей фильтров

Legal Events

Date Code Title Description
MA4A Surrender of the eurasian patent at the request of the proprietor in the following designated state(s)

Designated state(s): TJ